Longeveron
LGVNLongeveron is a clinical-stage biotechnology company focused on developing regenerative medicines to address life-threatening and chronic aging-related conditions.
$20.55M-8.7%
Table of contents
Earnings
Next report
Aug 12, 2026 (in a month)Revenue estimate$326.0K
EPS estimate-$0.19
Competitors
Profile
Longeveron is a clinical-stage biotechnology company focused on developing regenerative medicines to address life-threatening and chronic aging-related conditions. The company's core value proposition centers on its proprietary allogeneic cellular therapy, Lomecel-B, which utilizes pro-vascular and anti-inflammatory mechanisms to promote tissue repair and healing.
Competitive position
A clinical-stage player specializing in allogeneic bone marrow-derived mesenchymal stem cells with a focus on rare pediatric cardiac indications and aging-related frailty.
GeographiesUnited States
Customer segmentsPatients with unmet medical needs, Biopharmaceutical companies
Business modelR&D intensive, B2B service provider
SuppliersFresh bone marrow suppliers, Contract Development and Manufacturing Organizations (CDMO), Laboratory equipment providers
CustomersSpecialized pediatric hospitals, Geriatric care centers, Clinical research organizations
CountryUnited States of America
Listed2021
Employees24.0
CEOStephen H. Willard
SectorHealthcare
IndustryBiotechnology
Websitelongeveron.com
FilingsSEC EDGAR
Questions, answered.
- What is Longeveron's market cap?
- Longeveron (LGVN) has a market capitalization of $20.6M and trades on NASDAQ.
- Who are Longeveron's competitors?
- Longeveron's key competitors include Mesoblast Limited, Creative Medical Technology Holdings, Inc. Common Stock, FibroBiologics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Longeveron headquartered?
- Longeveron is headquartered in United States of America and employs approximately 24 people. It has been publicly traded since 2021.